Evidence Hub

Gut microbiota-derived metabolites in prostate cancer: a network pharmacology-based identification

Wang Y, Chen L

2026

Abstract

Abstract Recent studies have indicated that microbial metabolites produced by the gut microbiota can influence the progression of prostate cancer (PCa). To identify metabolites with therapeutic potential for PCa and to further clarify the mechanisms by which gut microbial metabolites regulate PCa progression, a novel and comprehensive perspective is required. Here, network pharmacology was used to screen 277 metabolites recorded in the gutMGene database. Through the combined application of metabolite target databases and disease target databases, we ultimately identified 34 core targets mediating the impact of gut microbial metabolites on PCa. Enrichment analyses showed that these metabolites may affect PCa progression by modulating the PI3K-AKT and MAPK pathways. Molecular docking results showed that quercimeritrin bound well to IL-6, whereas quercetin, indole-3-lactic acid, and 3-indolepropionic acid bound well to AKT1. These findings offer new perspectives on how gut microbial metabolites may regulate PCa and suggest novel avenues for drug discovery against this disease.

How strong is the evidence?

Evidence Hub reads this as a preprint, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free